Loading...
Sign up
Log in
Dashboards
Latest
Sectors
Earnings
IPOs
Splits
Institutional
Insider
Reddit
Share this news
Latest AXGN news
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
24 Feb 21
Biotech, Earnings, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, Top Stories, Pre-Market Outlook, General
Stocks Making New 52-Week Highs/Lows For Tuesday, Feb. 23, 2021 (Via Benzinga Pro's Signals Tool)
23 Feb 21
Movers, Trading Ideas
Stocks That Hit 52-Week Highs On Tuesday
23 Feb 21
News, Intraday Update, Markets, Movers, Trading Ideas
Canaccord Genuity Maintains Hold on Axogen, Raises Price Target to $21
23 Feb 21
News, Price Target, Analyst Ratings
10 Biggest Price Target Changes For Tuesday
23 Feb 21
Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
AXGN
Dashboard
Financials
Data
Institutional
Insider
News
Filings
Transcripts
Reddit
ESG
Shorts
Patents
Article
AXGN
Dashboard
Financials
Data
Institutional
Insider
News
Filings
Transcripts
Reddit
ESG
Shorts
Patents
Article
SVB Leerink Maintains Outperform on Axogen, Raises Price Target to $27
Tue. 23 Feb 2021, 4:45am ET
Benzinga
In: News, Price Target, Analyst Ratings
AXGN
SVB Leerink analyst Richard Newitter maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $23 to $27.
